Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 527

The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.

State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines

Open access
Dawidczyk, Charlene M., Kim, Chloe, Park, Jea Ho, Russell, Luisa M., Lee, Kwan Hyi, Pomper, Martin G., Searson, Peter C.·2014·Journal of Controlled Release
DOI 10.1016/j.jconrel.2014.05.036
Open this paper in CoChat — free account

Abstract

The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2014.05.036

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 110 references

Cited by

See all 527

Metadata

Authors
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2014-08
Volume
187
Pages
133-144
ISSN
0168-3659 (ISSN-L)
DOI
10.1016/j.jconrel.2014.05.036
OpenAlex
W2146205672
Cited by
527
References
110
FWCI
19.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. https://app.cochat.ai/papers/10.1016/j.jconrel.2014.05.036
The paper
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014). State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2014.05.036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.